On the contrary, no significant difference was reported in terms of OS and PFS between KRAS G12C and non- KRAS G12C patients treated with chemotherapy alone or in combination with checkpoint inhibitor as first-line treatment for advanced or metastatic NSCLC (32). This evidence concerns the gene KRAS and non-small cell lung carcinoma.